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Background: Plasmodium parasites rely on various host factors to 
grow and replicate within red blood cells (RBC). While many host 
proteins are known that mediate parasite adhesion and invasion, few 
examples of host enzymes co-opted by the parasite during 
intracellular development have been described. Recent studies 
suggested that the host protein Argonaute 2 (Ago2), which is involved 
in RNA interference, can translocate into the parasite and affect its 
development. Here, we investigated this hypothesis. 
Methods: We used several different monoclonal antibodies to test for 
Ago2 localisation in the human malaria parasite, P. falciparum and 
rodent P. berghei parasites. In addition, we biochemically fractionated 
infected red blood cells to localize Ago2. We also quantified parasite 
growth and sexual commitment in the presence of the Ago2 inhibitor 
BCI-137. 
Results: Ago2 localization by fluorescence microscopy produced 
inconclusive results across the three different antibodies, suggesting 
cross-reactivity with parasite targets. Biochemical separation of 
parasite and RBC cytoplasm detected Ago2 only in the RBC cytoplasm 
and not in the parasite. Inhibition of Ago2 using BCl-137 did not result 
in altered parasite development. 
Conclusion: Ago2 localization in infected RBCs by microscopy is 
confounded by non-specific binding of antibodies. Complementary 
results using biochemical fractionation and Ago2 detection by western 
blot did not detect the protein in the parasite cytosol, and growth 
assays using a specific inhibitor demonstrated that its catalytical 
activity is not required for parasite development. We therefore 
conclude that previous data localising Ago2 to parasite ring stages are 
due to antibody cross reactivity, and that Ago2 is not required for 
intracellular Plasmodium development.
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            Amendments from Version 1
In the revised version, we have addressed the concerns raised 
by the reviewers. In particular, both reviewers pointed out that 
the original data suggesting Ago2 localisation to the parasite 
were made in the P. falciparum 3D7 strain, while most of the data 
presented in this MS has been obtained with the Pf2004 strain. 
We thus reproduced the Western blot of fractionated samples 
with 3D7 to exclude the possibility of strain-specific differences in 
Ago2 localisation (new figure panel 3B, new Extended  
figure 3). As anticipated we did not observe a band for Ago2 in 
the parasite fraction. 
The reviewers also noted the lack of a positive control for the 
Ago2 inhibition assay. As RBCs are not transcriptionally active, we 
cannot test for Ago2 activity in those cells, and we believe testing 
the activity of BCI-137 in other cell types to be not informative. 
However, it is important to note that the concentration range of 
BCI-137 we used exceeds the concentrations previously shown 
to inhibit Ago2-miRNA binding (Masciarelli et al., ACS Chem Biol., 
2014). We have now expanded on this limitation in the text. As 
minor changes, we corrected the RRID and supplier version 
for the antibody 2E12-1C9, added the reference for the strain 





Malaria, caused by the protozoan parasite Plasmodium, remains 
a devastating disease affecting over 200 million people per 
year1. Clinical symptoms are initiated when parasites invade 
and replicate within red blood cells (RBCs). Several potent anti-
malarials are available, yet drug resistance is spreading as tar-
geted Plasmodium proteins and pathways are amenable to 
mutation2. Host factors required for Plasmodium development 
could potentially offer novel drug targets that are less prone to 
resistance mutations3,4. However, while host receptors essential 
for parasite invasion into the RBC are intensively studied, little 
is known about host factors required for parasite growth and 
development within the RBC.
Studies by us and others have suggested possible involve-
ment of the host protein Argonaute 2 (Ago2) in parasite 
development5,6. In many eukaryotic systems Ago proteins 
are core proteins of the RNA interference (RNAi) machin-
ery. Directed by the complementary sequence of microRNAs 
(miRNAs), Ago proteins bind to target mRNAs and either sup-
press translation, or, in case of Ago2, the only catalytically 
active Ago protein in mammalians, directly cleave the mRNA 
target7,8. While mature RBCs lack a nucleus and thus de novo 
transcription, Ago2-mediated RNAi is important for RBC 
maturation from haematopoietic stem cells9–11, i.e. erythropoiesis. 
Ago2 is essential for non-canonical processing and maturation 
of the miRNAs miR-451 and miR-486, major miRNAs involved 
in erythropoiesis12,13. Moreover, Ago2 and several miRNAs, 
including miR-451, are found in P. falciparum-infected and 
uninfected reticulocytes and mature RBCs14–17. We and 
others have found previously that infected RBCs (iRBCs) shed 
increased amounts of extravascular vesicles (EVs) compared 
to uninfected RBCs5,6. These iRBC-derived EVs contain Ago2-
miRNA complexes that can alter endothelial cell function 
via RNAi, suggesting a contribution to vascular dysfunction 
during malaria infection5. Intriguingly, we also localised 
host Ago2 to the parasite cytoplasm of ring-infected RBCs, 
suggesting possible Ago2 activity in the parasite5,6. Plasmodium 
parasites do not have an RNAi machinery including Ago 
proteins18. To enable manipulation of gene expression via RNAi, 
we have previously demonstrated successful expression of a 
human core RNAi machinery in the murine model Plasmodium 
berghei (P. berghei)19. Interestingly, we observed that the ectopic 
expression of Ago2 in P. berghei induced a minor growth defect 
in asexual parasite stages and downregulation of genes known 
to be targeted by post-transcriptional repression in female 
sexual stages (gametocytes). These observations show that 
Ago2 can interfere with parasite gene expression, supporting 
the hypothesis that host Ago2 is involved in Plasmodium 
blood stage development. Indeed, a recent study suggested 
that host Ago2 can downregulate virulence gene expression in 
P. falciparum as part of an innate resistance mechanism of the host 
RBC against the parasite6.
In this work, we aimed to validate the localisation of host Ago2 
to blood stage parasites and investigate if catalytically active 
host Ago2 is required for parasite development. Our data 
demonstrate that previously observed Ago2 localisation in the 
parasite by fluorescence microscopy is the result of antibody 
cross reactivity. Importantly, we detected no Ago2 in para-
sites when performing Western blotting on fractionated parasite 
samples, and inhibition of Ago2 catalytical activity did not 
impact asexual parasite growth and parasite development. 
We thus conclude that, at least in vitro, Ago2 is not a host 
factor important for intraerythrocytic parasite development.
Methods
Ethics statement
All animal experiments were performed according to European 
regulations concerning FELASA category B and GVSOLAS 
standard guidelines. Animal experiments were approved 
by German authorities (Regierungspraesidium Karlsruhe, 
Germany), § 8 Abs. 1 Tierschutzgesetz (TierSchG) under the 
license G-260/12 and were performed according to National 
and European regulations. Two female outbred NMRI mice 
(8- to 10-week-old) purchased from Janvier laboratories, 
France, were used. Mice were kept in groups of 2 to 4 mice per 
cage under specified pathogen-free (SPF) conditions within 
the animal facility at Heidelberg University (IBF) on a 12-hour 
light/dark cycle at 22°C (± 2°C) with ad libitum access to food 
and water.
P. falciparum in vitro culture
Parasite culture was performed as described previously20. 
P. falciparum parasites (strains 3D7, NF54 and 200420) were 
kept in fresh type 0+ human erythrocytes (NHS National Serv-
ices Scotland), suspended at 5% hematocrit in HEPES-buffered 
RPMI 1640 medium (Gibco™ 22400089) supplemented with 
10% (w/v) heat inactivated human serum (Interstate Blood 
Bank), 0.05 mg/ml hypoxanthine (Gibco™) and 50 ng/ml gen-
tamycin (Gibco™). To maintain the plasmid encoding the 
gametocyte reporter TdTomato, Pf2004 parasites were kept 
under 4 nM WR99210 (Jacobus Pharmaceuticals) selection 
pressure. Cultures were kept in a controlled environment at 
37°C in a gassed chamber at 5% CO
2
 and 1% O
2
.
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P. falciparum gametocyte commitment and mature 
gametocyte production
Parasite sexual commitment assay was performed as described 
previously20. Briefly, sorbitol-synchronised P. falciparum 2004 
parasites expressing TdTomato under the gametocyte promoter 
etramp10.3 (PF10_0164/PF3D7_1016900)20 were seeded at 
24 hpi, 0.5% parasitemia into a 96-well plate adding varying 
BCI-137 (Merck-Millipore) concentrations (100 µM, 10 µM, 
1 µM, 100 nM, 10 nM, 1 nM). For vehicle control, 1 % (v/v) 
and 0.1% DMSO (corresponding to 100 µM and 10 µM 
BCI-137, respectively), were added to parasites. Sexual 
commitment was induced by incubation in LysoPC-depleted 
minimal-fatty-acid medium for 24 h, while controls were 
maintained in complete medium. Medium was changed daily 
maintaining drug pressure. Parasitemia was assessed by SYBR 
green staining and flow cytometry on day 0, day 2 and day 4 
post induction. On day 4, gametocytemia was determined as per-
centage of TdTomato-positive parasites. Parasite multiplication 
rate was calculated by dividing parasitemia on day 2 by starting 
parasitemia on day 0, sexual commitment was calculated by 
dividing gametocytemia on day 4 by parasitemia on day 2.
For production of mature gametocytes, sexual commitment 
of the PfNF54 strain was induced as described above. After 
induction, asexual development was suppressed by addition 
of heparin to a final concentration of 0.23 mg/ml to the culture 
medium on days 2, 3 and 4 after induction. Mature gametocytes 
were obtained after 14 days of culture and fixed and stained 
for immunofluorescence assays (IFAs) as described below.
P. berghei infections
A female NMRI mouse was infected with P. berghei ANKA 
parasites by intraperitoneal injection of a cryostock containing 
approximately 1.5 *10^7 infected RBCs in 100 µl blood and 
200 µl freezing solution (10% glycerol in alsevier solution). 
Once parasitemia reached about 2–3%, the mouse was anaes-
thetised using an overdose of isoflurane and bled by cardiac 
puncture, and the blood processed for microscopy, as described 
below.
IFAs
IFAs were done as described previously21. Mixed-stage cul-
tures of Pf3D7 parasites, sorbitol-synchronised Pf2004 para-
sites at 10, 22, 36, and 44 hours post invasion, mature PfNF54 
gametocytes or P. berghei ANKA parasites were collected and 
pelleted for 3 min at 1600 rpm. 50 µl RBC pellet were fixed in 
1 ml 4% paraformaldehyde (PFA)/0.0075% glutaraldehyde for 
20 min at 37°C. Cells were pelleted for 1 min at 3000 rpm and 
permeabilised in 1 ml 125 mM Glycine/0.1% Triton-X-100 in 
PBS for 10 min at RT. After pelleting and washing once with 
3% BSA/PBS, cells were blocked overnight in 3% BSA/PBS. 
Primary antibodies were used at a dilution of 1:50 and incubated 
for 2 h at RT, shaking. RBCs were pelleted and washed 3 times 
for 10 min with 1% BSA/PBS. Secondary antibodies were 
diluted 1:300 in 3% BSA/PBS and incubated for 1 h at RT. 
RBCs were pelleted and washed 3 times for 10 min with PBS. 
The first washing step included Hoechst in a 1:3000 dilution to 
stain DNA. Primary and corresponding secondary antibodies 
used are depicted in Table 1.
For imaging, 2 µl of stained parasite pellet were placed onto 
a glass slide and covered with a coverslip. Imaging was per-
formed on a confocal spinning disc microscope (Nikon) using a 
100x objective or a widefield DMi8 microscope (Leica) using 




Rabbit-αAgo2 (EPR10411), Abcam Cat# 
ab186733, RRID:AB_2713978
Goat-αRabbit, Alexa Fluor 488, Thermo 
Fisher Scientific Cat# A-11008, RRID:
AB_143165
IRDye® 680RD Donkey anti-Rabbit IgG 
Secondary Antibody, LI-COR Biosciences 
Cat# 926-68073, RRID:AB_10954442
Mouse-αAgo2 (2E12-1C9), Abcam Cat# 
ab57113, RRID:AB_2230916
Goat-αMouse, Alexa Fluor 488, Thermo 
Fisher Scientific Cat# A-11001, RRID:
AB_2534069 
Goat-αMouse, Alexa Fluor 594, Thermo 
Fisher Scientific Cat# A-11032, RRID:
AB_2534091
IRDye® 680RD Donkey anti-Mouse IgG 
Secondary Antibody, LI-COR Biosciences 
Cat# 926-68072, RRID:AB_10953628
Rat-αAgo2 (11A9), Thermo Fisher Scientific 
Cat# 14-6519-82, RRID:AB_2784637
Goat-αRat, Alexa Fluor 488, Thermo Fisher 
Scientific Cat# A-11006, RRID:AB_2534074 -
Mouse-α PbHsp70, RRID:AB_265048224
Goat-αMouse, Alexa Fluor 594, Thermo 
Fisher Scientific Cat# A-11032, RRID:
AB_2534091
-
Mouse α-αTubulin, Sigma-Aldrich Cat# 
T5168, RRID:AB_477579
Goat-αMouse, Alexa Fluor 594, Thermo 
Fisher Scientific Cat# A-11032, RRID:
AB_2534091
-
Rabbit-αPfBIP (antibody provided by MR4; 
clone MRA1925, RRID:AB_2716735) -
IRDye® 800CW Donkey anti-Rabbit IgG 
Secondary Antibody, LI-COR Biosciences 
Cat# 926-32213, RRID:AB_621848
Mouse-αHsHsp70, Santa Cruz Biotechnology 
Cat# sc-24, RRID:AB_627760 -
IRDye® 800CW Donkey anti-Mouse IgG 
Secondary Antibody, LI-COR Biosciences 
Cat# 926-32212, RRID:AB_621847
IFA: Immunofluorescence assay, WB: Western blot.
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Figure 1. Localisation of Ago2 to the iRBC. (A) IFA of P. falciparum 3D7 blood stages. Yellow: Ago2 (EPR10411), magenta: PfTubulin. (B) IF 
staining of P. berghei ANKA rings and trophozoites. Yellow: Ago2 (EPR10411), magenta: PbHsp70. Nuclei were stained with Hoechst (blue). 
Images were taken on a Nikon spinning disc confocal microscope (100x objective). Representative images of at least 5 per condition are 
shown. Controls using only a secondary antibody revealed no unspecific staining. Scale bar indicates 5 µm.
Parasite fractionation and western blotting
P. falciparum Pf2004 or 3D7 cultures were sorbitol-synchro-
nised and harvested at 10, 22, 36 and 44 hpi and a parasitemia 
of 5% by pelleting for 3 min at 1600 rpm. For the total sample, 
1x109 RBCs were washed in 1 ml PBS and resuspended to a 
final volume of 500 µl parasite lysis buffer supplemented with 
1x protease inhibitor cocktail (PIC). For fractionation, 2×109 
RBCs were washed in 1 ml PBS and lysed for 5 min on ice in 
1 ml final volume of 0.015 % saponin/PBS (w/v). After 3 min 
centrifugation at full speed, the supernatant was transferred 
to a new tube and supplemented with 1x PIC. The pellet was 
washed 3 times in 1 ml PBS and resuspended in 50 µl parasite 
lysis buffer supplemented with 1x PIC.
For western blotting, samples were denatured in 1x SDS load-
ing dye/0.05 M DTT for 5 min at 95°C and 4×106 RBCs 
(total and supernatant) or 2×107 iRBC (pellet) per lane were 
separated on a 4–12% Bis-Tris protein gel (NuPage™) and 
transferred onto Amersham Hybond LFP 0.2 PVDF Western 
blotting membranes (GE Life Sciences). Blots were blocked for 
1 h in 1% fish gelatin/TBS and primary antibodies (Table 1, 
dilution 1:300) incubated over night at 4 °C. Secondary anti-
bodies (Table 1) were diluted 1:20000 in 1% fish gelatin/0.01% 
SDS/TBS-T and incubated for 1 h at RT. Blots were developed 
on a Licor Odyssey® CLx. Images of the whole blots are depicted 
in Extended data, Extended Figure 1 and 226. Raw western 
blot images are available as Underlying data27.
Results
Ambiguous Ago localization in parasite and host cell by 
fluorescence microscopy
In a first step, we aimed to verify the previously published 
results of Ago2 localisation to P. falciparum ring stages. To 
this end, we performed IFAs on mixed P. falciparum 3D7 and 
P. berghei ANKA blood stages using the commercial Ago2 
antibody EPR10411, which binds to a central peptide epitope 
of human and murine Ago2. We observed a clear punctuate 
pattern of host Ago2 in the cytoplasm of all asexual stages of 
P. falciparum, as well as P. berghei rings and, to a lesser extent, 
trophozoites (Figure 1A, B).
As this localisation is in contrast to the previous reports 
which detected Ago2 only in ring stage parasites, we repeated 
the experiment with two additional commercial monoclonal 
antibodies (mAbs): 2E12-1C9, which has previously been 
used5,6, and 11A9, which has not been tested with Plasmodium 
before. The clone 2E12-1C9 was raised against the Ago2 
C-terminus (target epitope unknown), while clone 11A9 was 
raised against a N-terminal peptide. The respective Ago2 target 
sites of the different antibodies are depicted in Figure 2A. All 
three Ago2 antibodies detected Ago2 as punctuate structures 
in the RBC cytoplasm and close to the membrane, match-
ing the previously published localisation of Ago2 
in uninfected RBC ghosts17. However, the antibodies showed 
only minor overlap in localization, suggesting some non-specific 
reactivity (Figure 2B).
To investigate the localization of these antibodies in iRBCs, 
we used synchronised Pf2004 parasites at 10, 22, 36 and 
48 hpi, as well as mature gametocytes. Again, only minor overlap 
in parasite staining was observed across the different 
antibodies used (Figure 2C). While EPR10411 labelled all 
asexual stages (see also Figure 1A) and a fraction of mature 
P. falciparum gametocytes, 2E12-1C9 only stained 10 hpi 
ring stages, replicating the previously published data with this 
antibody5,6. In contrast, 11A9 did not localise to any stage of the 
parasites (Figure 2D). In conclusion, three different antibodies 
directed against Ago2 resulted in three different staining 
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patterns in IFAs strongly suggesting that at least part of the 
signal is non-specific. Raw images used to generate Figure 1 and 
Figure 2 are available as Underlying data27.
No evidence for Ago2 localization in the parasite by 
biochemical fractionation
To independently investigate Ago2 localisation in parasite and 
host cell, we performed fractionation experiments followed by 
western blotting. Synchronised P. falciparum Pf2004 or Pf3D7 
parasites at 10, 22, 36 and 44 hpi were lysed using saponin 
and separated into a supernatant fraction containing the RBC 
cytoplasm and parasitophorous vacuole (PV) content, and the 
pellet containing membranes and parasite cytoplasm. Western 
blots of total, supernatant and pellet samples were probed for 
Ago2 using the antibodies 2E12-1C9 and EPR10411, which 
both detected Ago2 signal in parasites by IFA (Figure 1A, 
Figure 2C). As controls for the fractionation protocol we used 
antibodies against the RBC cytosol protein human heat shock 
protein 70 (hHsp70) and the parasite ER protein PfBIP. In 
non-fractionated (total) samples, we detected bands correspond-
ing to Ago2, hHsp70 and PfBIP (Figure 3A, B, left panels). As 
expected, hHsp70 was only detected in the RBC cytosol (RBC, 
middle panels), while PfBIP was only detected in the parasite 
(right panels), indicating clean separation of these two frac-
tions. Intriguingly, both antibodies against Ago2 detected a band 
corresponding to the expected size of Ago2 only in the super-
natant fraction (RBC cytosol), independent of parasite stage. 
No other bands were detected across the whole blots (Extended 
Figure 2. Further analysis of Ago2 localization to the iRBC. (A) Binding sites of αAgo2 antibodies used. The monoclonal antibodies 
11A9 and EPR10411 were raised against an N-terminal and a centrally located peptide epitope, respectively. The antibody 2E12-1C9 is a 
monoclonal antibody raised against the whole C-terminus of hAgo2. (B) IFA of uninfected RBCs. Yellow: Ago2 (EPR10411), magenta: Ago2 
(either 2E12-1C9 (top) or 11A9 (bottom)). (C) IFA of P. falciparum 2004 parasites at 10, 22, 34 and 46 hours post invasion (hpi) and mature 
PfNF54 gametocytes. Yellow: Ago2 (EPR10411), magenta: Ago2 (2E12-1C9). Contrast and brightness of EPR10411 panels were individually 
adjusted to optimise image quality, thus, signal strength cannot be compared between panels. (D) IFA of P. falciparum 2004 parasites at 
10 and 46 hpi. Yellow: Ago2 (EPR10411), magenta: Ago2 (11A9). Nuclei were stained with Hoechst (blue). Images were taken on a Leica 
widefield microscope (60x objective). Representative images of at least 5 per condition are shown. Controls using only a secondary antibody 
revealed no unspecific staining. Scale bar indicates 5 µm.
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data, Extended Figures 1, 2A, B)26. This finding contradicts our 
IFA data (Figure 1, Figure 2) and suggests that Ago2 is not 
localized to the parasite.
Inhibition of Ago2 function does not affect parasite 
growth
To directly investigate whether host Ago2 plays a role in blood 
stage malaria parasites, we tested the effect of an Ago2 inhibitor 
against P. falciparum parasites. BCI-137 is a cell permeable 
Ago2 inhibitor that prevents miRNA-binding and thus function-
ally inhibits Ago228. First, we tested the effect of BCl-137 on 
parasite growth using a dilution series of the compound. As a 
previous study inhibiting the host protein acylpeptide hydrolase 
only observed an inhibitory effect after two asexual replication 
cycles29, we quantified parasite multiplication rate (PMR) for two 
consecutive cycles but observed no change in PMR compared 
to vehicle (DMSO) up to 100 µM of compound (Figure 4A). 
We also tested the effect on gametocyte production using our 
previously published assay to induce sexual commitment via 
depletion of LysoPC20, and again no phenotype was observed 
(Figure 4B). A higher concentration of 1 mM BCI-137 led to 
a decreased PMR and increased sexual commitment, yet this 
was due to toxic concentrations of the solvent DMSO 
(Extended data, Extended Figure 3)26. Flow cytometry output 
files are available as Underlying data27. Altogether these data 
demonstrate that inhibition of Ago2 function with BCI-137 does 
not affect parasite multiplication rate or gametocyte production, 
even at micromolar concentrations.
Discussion
In this study we have followed up previous reports describing 
the unusual localisation of a host protein, Ago2, in the intracel-
lular blood stages of Plasmodium parasites. Malaria parasites 
take up nutrients from the host cell environment through non-
selective pores in the parasitophorous vacuolar membrane 
(PVM)30,31. Large scale uptake of host cytosolic material into 
the parasite, including haemoglobin and other essential nutri-
ents, is additionally facilitated by a recently characterized 
Figure 3. Western blot of fractionated P. falciparum-infected iRBCs. A) Pf2004 or B) Pf3D7  iRBCs at 10, 22, 34 and 46 hours post 
invasion (hpi) were separated via saponin lysis into erythrocyte cytoplasm and PV content (RBC) and parasite cytoplasm and membranes 
(parasite). Western blot analysis was performed on total protein (left panel, 20 % loaded), saponin supernatant containing RBC and PV 
cytoplasm (middle panel, 20 % loaded) and pellet containing parasite cytoplasm (right panel, 100 % loaded). Antibodies targeting the RBC 
housekeeper hHsp70 (expected size human Hsp70: 70 kDa) and the parasite housekeeper PfBIP served as control for proper fractionation. 
Using two Ago2 antibodies, Ago2 was only detected in the total and the RBC fraction (expected size Ago2 95 kDa).
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Figure 4. Parasite growth and commitment  in presence of an  inhibitor of hAgo2. Pf2004 parasites were treated with the Ago2 
inhibitor BCI-137 at various concentrations or vehicle (DMSO) and assessed for asexual parasitemia and gametocytemia by flow cytometry. 
A) Parasite multiplication rate (PMR) over two cycles of asexual replication. B) Gametocyte conversion rate under non-induced and 
gametocyte-induced conditions. Note: no RBC control is included as it is not possible to directly measure Ago2 activity in RBCs due to their 
lack of transcriptional activity. However, we used the inhibitor at a tenfold higher maximal concentration compared to what has been shown 
to be sufficient to inhibit Ago2-miRNA binding28. Shown is the mean ± SD of n = 2, with 3 technical replicates each.
endocytosis pathway32. Parasites also take up host enzymes and 
co-opt their function, as demonstrated by the import of human 
peroxiredoxin 2 for peroxide detoxification33 or of erythrocyte 
acylpeptide hydrolase29.
The reported localisation of Ago2 in early ring stage parasites 
and the observed phenotype upon Ago2 over-expression 
prompted us to investigate if indeed host Ago2 function had also 
been co-opted by the malaria parasite. We used three independ-
ent approaches to test for a possible role of Ago2 in parasite 
development. First, we localised Ago2 in iRBCs using a series 
of monoclonal antibodies that provided ambiguous results. Sec-
ond, we fractionated iRBCs into host cytoplasm and parasite 
and performed Western blotting with two antibodies target-
ing Ago2, demonstrating Ago2 in the RBC fraction only. Third, 
we measured parasite growth and sexual commitment upon 
incubation with the Ago2 inhibitor BCI-137, resulting in no 
discernible phenotype.
In nucleated cells, Ago2 is known to localise both to the cyto-
plasm and to cytoplasmic ribonucleoprotein granules, e.g. GW/P 
bodies or stress granules, which are sites of miRNA-mediated 
mRNA degradation34,35. To our knowledge, it has not yet been 
investigated if such granules are present in erythrocytes and the 
subcellular localisation of Ago2 in RBCs is unknown, with the 
exception of one study which localised Ago2 to punctuate struc-
tures close to the membrane of erythrocyte ghosts; no locali-
sation in the RBC cytoplasm was performed17. In the present 
work, we observed a speckled localisation for Ago2 within the 
erythrocyte, resembling the punctuate localisation of Ago2 to 
P bodies in nucleated cells34. However, in our hands, none of 
the three different commercial antibodies against Ago2 showed 
substantial co-localisation in IFA studies. Antibody 2E12-1C9 
is known to cross-react with Ago1, Ago3 and Ago4, yet eryth-
roid cells almost exclusively express Ago212. Ago2 is subject to 
a variety of posttranslational modifications, some of which can 
alter the subcellular localisation of the protein36. For example, 
phosphorylation of Ago2 at position Ser387 increases its locali-
sation to P bodies37. Intriguingly, the epitope for the anti-
body EPR10411 encompasses Ser387, and phosphorylation at 
this site might affect binding of the antibody to Ago2. Other 
post-translational modifications might exist at the epitopes for 
the other antibodies, and it is thus tempting to speculate that 
the different antibodies recognise different subpopulations of 
post-translationally modified Ago2 in the RBC.
Using three different antibodies, we also observed ambiguous 
Ago2 staining in the parasite, with the antibody 11A9 not 
localizing to the parasite at all, the antibody 2E12-1C12 local-
izing only to ring stages, and the antibody EPR10411 to 
all asexual parasites and some gametocytes. Importantly, we did 
not detect Ago2 in the parasite fraction at any time point of the 
asexual cycle by western blot using two different antibodies, 
arguing against the presence of Ago2 in the parasite cytoplasm. 
We previously detected a weak band in the parasite fraction 
of trophozoites with one of these antibodies5. This may have 
been the result of incomplete separation of the fractions, as in 
absence of an antibody targeting a cytoplasmic RBC marker 
protein, a contamination of the parasite fraction with host cytosol 
protein cannot be excluded. Similarly, a western blot in another 
study demonstrated Ago2 in the parasite fraction, but lacked 
appropriate controls to demonstrate clean fractionation6.
In absence of a Plasmodium Ago2 homologue, it remains 
unknown which parasite protein is detected by αAgo2 antibodies 
in IFAs. A BLAST search with the sequence of the linear peptide 
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epitope of the antibody EPR10411 (as obtained from the sup-
plier) against a Pf database did not yield any meaningful match. 
In addition, Western blotting of parasite fractions did not yield 
any clean band across the whole blot (Extended data, Extended 
Figures 1,2)26, indicating that the observed Ago2 localiza-
tion in the parasite with both antibodies using IFA is the result 
of cross reactivity with a conformational parasite epitope. In 
IFAs, EPR10411 produced a specific and strong signal across 
all parasite stages which increased during asexual development, 
while 2C12-E2 was only detected in early ring stages, suggest-
ing that the two antibodies cross-react with different parasite 
antigens.
We also did not observe any inhibitory effect using the 
membrane-permeable drug BCI-137 on parasite development. 
This finding is in line with previous observations that ectopic 
expression of Ago2-dependent miRNAs in P. berghei does not 
regulate gene expression in absence of ectopically expressed 
Ago219. Altogether our data do not support the hypothesis 
that Ago2 is transferred from host to parasite, and/or that it 
performs a relevant role in parasite development.
Our study emphasises the importance of using proper 
controls and orthogonal methods to corroborate initial findings. 
Notably, the Ago2 antibody 11A9 has been previously reported 
to cross-react with the nuclear protein SMARCC1 in chro-
matin immunoprecipitation (IP) studies38. Given that we were 
not able to detect Ago2 in Plasmodium, we presume that pre-
vious results of an Ago2-IP from parasites were also influ-
enced by cross reactivity6. In summary, we conclude that there 
is no Ago2-mediated miRNA activity in malaria parasites, 
despite a previous report suggesting otherwise.
Data availability
Underlying data
Figshare: No evidence for Ago2 translocation from the host 
erythrocyte to the Plasmodium parasite. https://doi.org/10.6084/
m9.figshare.c.496064927.
This project contains the following underlying data: 
•     Figure 1B - PbANKA + EPR10411 - Raw Image Files 
(TIF; https://doi.org/10.6084/m9.figshare.12229037).
•     Figure 1B - Pf3D7 + EPR10411 - Raw Image Files 
(TIF; https://doi.org/10.6084/m9.figshare.12229050).
•     Figure 2D - Figure 2D - EPR10411 + 2E12-1C9 - Raw 
Image Files (TIF; https://doi.org/10.6084/
m9.figshare.12229107).
•     Figure 3 - Western Blots Raw Data (TIF; https://doi.
org/10.6084/m9.figshare.12229169).
•     Figure 4, Extended Figure 1 - Flow Cytometry Raw Data 
(XLSX; https://doi.org/10.6084/m9.figshare.12229160).
Extended data
Figshare: Extended Figures 1 and 2. https://doi.org/10.6084/m9. 
figshare.1222902826.
This project contains the following extended data: 
•     Extended Figure 1 (PDF). Whole blots of Western blot 
of fractionated P. falciparum-infected iRBCs (strain 
Pf2004). iRBCs at 10, 22, 34 and 46 hours post invasion 
(hpi) were separated via saponin lysis into into erythrocyte 
cytoplasm and PV content (RBC) and parasite cyto-
plasm (parasite). Western blot analysis was performed 
on total protein (total, 20 % loaded), saponin supernatant 
containing RBC and PV cytoplasm (RBC, 20 % loaded) 
and pellet containing parasite cytoplasm (parasite, 100 % 
loaded). (A) Antibody αAgo2 2E12-1C9 (expected 
size Ago2 95 kDa). (B) Antibody αAgo2 EPR10411 
(expected size Ago2 95 kDa). (C) Antibody αhHsp70 
(expected size human Hsp70: 70 kDa). (D) Antibody 
αPfBIP (expected size 72 kDa). kDa: kilo Dalton, hpi: 
hours post invasion, M: Marker Li-Cor Chamaeleon 
DUO.
•     Extended Figure 2 (PDF). Whole Western blots of frac-
tionated P. falciparum-infected iRBCs (strain Pf3D7). 
iRBCs at 10, 22, 34 and 46 hours post invasion (hpi) were 
separated via saponin lysis into into erythrocyte cytoplasm 
and PV content (RBC) and parasite cytoplasm (parasite). 
Western blot analysis was performed on total protein (total, 
20 % loaded), saponin supernatant containing RBC and 
PV cytoplasm (RBC, 20 % loaded) and pellet containing 
parasite cytoplasm (parasite, 100 % loaded). (A) Antibody 
αAgo2 2E12-1C9 (expected size Ago2 95 kDa). (B) Anti-
body αAgo2 EPR10411 (expected size Ago2 95 kDa). 
(C) Antibody αhHsp70 (expected size human Hsp70: 
70 kDa). (D) Antibody αPfBIP (expected size 72 kDa). 
kDa: kilo Dalton, hpi: hours post invasion, M: Marker 
Li-Cor Chamaeleon DUO.
•     Extended Figure 3 (PDF). Parasite growth and 
commitment in presence of an inhibitor of hAgo2. 
Pf2004 parasites were treated with the Ago2 inhibitor 
BCI-137 at various concentrations or vehicle (DMSO) 
and assessed for asexual parasitemia and gameto-
cytemia by flow cytometry. (A) Parasite multiplication 
rate (PMR) over two cycles of asexual replication. 
(B) Gametocyte conversion rate under non-induced and 
gametocyte-induced conditions. DMSO (1%) is the 
vehicle control corresponding to 100 µM BCI-137, 0.1 % 
DMSO 1000 is the vehicle control corresponding to 
10 µM BCI-137. Shown is the mean ± SD of n = 2, with 
3 technical replicates each.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
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The manuscript by Hentzschel et al. revisited the localization and putative function of human Ago2 
in Plasmodium-infected erythrocytes. Recent studies, including a paper published in 2016 by the 
authors, suggested that hAgo2 can translocate into the parasite and affect its development. This 
prior work was partially based on IFA using a commercial monoclonal. 
Now the authors re-analyzed this localization by a comparative approach using several different 
monoclonal antibodies in P. falciparum and P. berghei infected erythrocytes and probed the 
function of hAgo2 in parasite maturation using the Ago2 inhibitor BCI-137. 
 
They show ambiguous localization patterns in IFAs within the parasite that point towards cross-
reactivity of the anti-Ago2 antibodies and does not support uptake of hAgo2 into the parasite. This 
finding was further supported by cell fractionation of parasite-infected erythrocytes that showed 
Ago2 only in the cytoplasm of the erythrocytes and not in the parasite. Additionally, the BCl-137-
based Ago2 inhibition over a wide concentration range did not result in altered parasite 
development. 
  
In my view, this work is an important contribution to the field because it sets the record straight 
using complementary techniques. It also highlights the challenges of using IFAs and the need for 
a very thorough validation of the antibodies used for protein localization.  
  
I have only a few additional comments on this well performed study: 
 
In their original study, the authors used 3D7 and show the staining of ring stage parasites 
by the monoclonal. In Fig. 2 C they provide their comparative localization study with Pf2004 
parasites. Although I very much doubt that there are any strain specific differences, for the 
sake of a direct comparison, 3D7 based localization would be beneficial. Side note: I could 
not find a reference for the Pf2004 parasite strain. 
○
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Ago2 inhibition (Fig. 4) – Granting that the authors are using BCl-137 in wide molar range, 
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This study expands on previous work by both the lead authors and others that identified a 
potential role for human Argonaute2 (Ago2), a protein involved in RNAi, in Plasmodium falciparum 
intraerythrocytic development. Two previous manuscripts established the presence of Ago2 in 
extracellular vesicles (EVs) released from P. falciparum infected erythrocytes, where it could 
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complex with microRNA and impact endothelial cell function. Both studies also reported the 
presence of Ago2 in P. falciparum parasites, rather than solely in the erythrocyte cytosol and 
released EVs, and some of this previous data implied that Ago2 might play a direct role in 
regulating P. falciparum development. In this study the authors compared multiple different 
commercial anti-Ago2 antibodies in both immunofluorescence and immunoblot experiments and 
the results suggested that the previous evidence for Ago2 localisation in P. falciparum parasites 
was due to antibody cross-reaction and incomplete fractionation. An Ago2 inhibitor had no impact 
on parasite development, and the authors therefore argue that there is no conclusive evidence for 
Ago2 activity in P. falciparum parasites. 
  
While this kind of study is perhaps unglamorous, it is an important addition to the scientific 
literature as it clarifies previous data, including data previously published by the authors 
themselves, and might prevent others pursuing hypotheses that are unlikely to be fruitful. It's 
indexing is therefore strongly supported. The experiments are generally clear and compelling, and 
the inclusion of full-length blots as extended figures are an example of publishing best practise 
that should be commended. While the overall case is clear, some minor details and controls would 
perhaps complete the story and completely show that the earlier indications of Ago2 functioning 
within P. falciparum parasites were misleading.
The authors show that three different anti-Ago2 antibodies result in different, non-
overlapping, staining patterns in P. falciparum infected erythrocytes, compelling evidence 
that they are recognising additional, non-Ago2, proteins at the dilutions used for 
immunofluorescence. The comparability of these data with the previous publications is 
clearly key. While one of the three antibodies, 2E12-1C9, is the same monoclonal used in 
both previous studies, each study used 2E12-1C9 from different suppliers. To rule out any 
possible confounding explanation for the different results (such as antibody mix up from 
certain suppliers), is it not possible to source exactly the same antibodies used in previous 
studies and compare them? 
 
1. 
Both previous studies used the P. falciparum 3D7 strain, but the key figures in this work 
used a different strain, Pf2004. While it would seem unlikely that Ago2 would play a strain-
specific role in parasite development, for completeness sake it would be useful to rule it out, 
for example by repeating the fractionation data in Figure 3 (which comprehensively argues 
against the presence of Ago2 in P. falciparum parasites) with 3D7. 
 
2. 
As noted above, Figure 3 is the most convincing data to rule out Ago2 in the parasite, but 
the methodology used differs subtly from the author’s previously published fractionation 
(ref 5), which used sequential tetanolysin then saponin fractionation. That approach 
indicated Ago2 was found in the parasite at the 24 hour time point only, and was found in 
the parasitophorous vacuole throughout parasite development. The authors argue that 
their previous data indicating Ago2 in the parasite was the result of incomplete 




Given the clear evidence of cross-reactivity of anti-Ago2 antibodies with a P. falciparum 
protein(s), and the presence of a few faint parasite bands recognised by anti-Ago2 
antibodies in the extended Figures, is there any indication what these cross-reacting 
proteins might be? If you BLAST a Pf database with just the segments of Ago2 used to raise 
antibodies, does anything come up at a convincing level of homology? 
4. 
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The BCI-137 inhibition data is clearly negative, but lacks a positive control to show that the 
concentrations used of this inhibitor from this supplier are active, for example by showing 
enzymatic inhibition, or inhibition of some other non-Plasmodium cell.
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